Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial (MIRAD trial)

Aim To investigate whether the mineralocorticoid receptor antagonist eplerenone has beneficial effects on liver fat and metabolism in patients with type 2 diabetes (T2D), the mineralocorticoid receptor antagonist in type 2 diabetes (MIRAD) trial. Material and methods In this 26‐week, double‐blind, r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2019-10, Vol.21 (10), p.2305-2314
Hauptverfasser:	Johansen, Marie L., Schou, Morten, Rossignol, Patrick, Holm, Maria R., Rasmussen, Jon, Brandt, Niels, Frandsen, Mikkel, Chabanova, Elizaveta, Dela, Flemming, Faber, Jens, Kistorp, Caroline
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics Antihypertensives Body fat Cardiovascular diseases Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Dosage Double-blind studies Epidermal growth factor receptors eplerenone Fat metabolism Glomerular filtration rate hyperkalaemia Hyperkalemia Insulin Lipid metabolism Liver liver fat Magnetic resonance spectroscopy Metabolism mineralocorticoid receptor antagonist
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!